Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services...

Descripción completa

Detalles Bibliográficos
Autores principales: Weberpals, Janick, Roumpanis, Spyros, Barer, Yael, Ehrlich, Sharon, Jessop, Nikki, Pedotti, Rosetta, Vaknin-Dembinsky, Adi, Brill, Livnat, Chodick, Gabriel, Rouzic, Erwan Muros-Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422340/
https://www.ncbi.nlm.nih.gov/pubmed/36081277
http://dx.doi.org/10.1016/j.msard.2022.104153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422340/
https://www.ncbi.nlm.nih.gov/pubmed/36081277
http://dx.doi.org/10.1016/j.msard.2022.104153

Ejemplares similares